GLP-1 costs: what can change month to month

GLP-1 medication costs are one of the most confusing parts of choosing a program. List prices exceed $1,000 per month for branded drugs, compounded alternatives advertise prices 70-85% lower, and telehealth providers bundle fees in ways that make apples-to-apples comparison difficult. This guide breaks down every component of a typical GLP-1 bill so you can compare programs on actual out-of-pocket cost, not marketing headlines.

Branded medication list prices

The wholesale acquisition cost (WAC) — commonly called the list price — for FDA-approved GLP-1 weight-management drugs as of early 2026:

• Wegovy injection (semaglutide 2.4 mg): approximately $1,349 per month at list price. Novo Nordisk offers self-pay pricing as low as $349/month through NovoCare Pharmacy.

• Wegovy pill (semaglutide 25 mg daily): approximately $1,349 per month at list price. Self-pay pricing starts at $149/month for lower doses and $299/month for the 25 mg maintenance dose.

• Zepbound (tirzepatide): approximately $1,059 per month at list price. Eli Lilly offers self-pay vials via LillyDirect at $299/month (2.5 mg), $399/month (5 mg), and $449/month (7.5-15 mg).

• Foundayo (orforglipron): Eli Lilly's newest oral option, available via LillyDirect starting at $149/month for the lowest dose.

• Saxenda (liraglutide 3.0 mg daily): approximately $1,349 per month at list price. A generic version from Teva launched in August 2025 at roughly $1,165/month wholesale.

These are list prices. What patients actually pay depends on insurance coverage, manufacturer savings cards, pharmacy benefit managers, and whether the patient uses a retail pharmacy, specialty pharmacy, or mail-order service.

Manufacturer savings programs and their limits

Both Novo Nordisk and Eli Lilly offer savings card programs that can reduce out-of-pocket costs significantly for commercially insured patients. Typical programs offer the first months at a reduced copay or a capped monthly cost. However, these programs have important limitations:

• Savings cards generally exclude patients with government insurance (Medicare, Medicaid, Tricare, VA).

• Maximum benefit limits apply — once the cumulative discount reaches a cap (often $150-$500 per fill), the patient pays the full copay or coinsurance.

• Savings programs are promotional and can be modified or discontinued at any time.

• Some programs require that the patient has commercial insurance that covers the drug; they supplement the copay rather than replacing insurance coverage entirely.

Compounded GLP-1 pricing

Compounded semaglutide and tirzepatide are typically priced between $150 and $500 per month, depending on the dose, the compounding pharmacy, and whether the telehealth provider marks up the medication cost. This price advantage is the primary driver of the compounded GLP-1 market.

However, the regulatory status of compounded GLP-1s is unstable. Following the FDA's determination that semaglutide is no longer in shortage, compounding pharmacies face legal challenges to continued production. Patients who start on compounded medication may need to transition to branded products — at significantly higher cost — if compounding access is restricted. Factor this transition risk into any cost comparison.

The anatomy of a telehealth program bill

When a telehealth provider advertises a monthly price, that number may include different combinations of the following components. Always ask which are included and which are billed separately:

• Medication cost: the drug itself, whether branded or compounded. This is typically the largest line item.

• Clinician or consultation fee: the charge for initial evaluation and ongoing prescriber access. Some programs charge a one-time intake fee ($50-$150) plus a separate monthly membership; others roll it into the medication price.

• Membership or platform fee: a recurring charge for access to the telehealth platform, messaging, content, and care coordination. Ranges from $0 (bundled) to $99/month (standalone).

• Shipping and cold-chain handling: injectable GLP-1s require temperature-controlled shipping. Some programs include this; others charge $10-$30 per shipment.

• Lab work: if the program requires blood tests, the cost may be $0 (included), passed through at the lab's cash rate ($50-$200), or billed to your insurance separately.

• Coaching or nutrition support: programs that include dietitian access, health coaching, or structured meal plans may charge a premium tier for these services.

Why the advertised price is rarely the real price

Telehealth providers have strong incentives to advertise the lowest possible number. Common tactics that make prices look lower than they are:

• ”Starting at” pricing: the advertised price applies to the lowest dose during the escalation phase, not the maintenance dose where patients spend most of their treatment.

• Introductory pricing: first-month or first-3-month promotional rates that increase significantly after the promotional period.

• Excluding mandatory fees: the headline price covers medication only, while consultation, shipping, and membership are billed separately.

• Per-week framing: advertising “$X per week” instead of the monthly total to make the number appear smaller.

• Bundle pricing: multi-month prepaid packages that reduce the effective monthly cost but require a larger upfront commitment with limited refund policies.

Insurance coverage landscape

Commercial insurance coverage for GLP-1 weight-management drugs has expanded significantly since 2023, but remains inconsistent. A 2025 KFF survey found approximately 1 in 5 large employers cover GLP-1s specifically for weight loss. Many plans cover the same drugs for type 2 diabetes but explicitly exclude the weight-loss indication. Prior authorization is almost universally required, and some plans have increased minimum BMI requirements or dropped weight-loss coverage entirely starting in 2026.

Medicare coverage is evolving rapidly. Historically, GLP-1s for weight loss were excluded from Part D. Beginning July 1, 2026, the Medicare GLP-1 Bridge program will cover Wegovy and Zepbound at $50/month for qualifying Part D enrollees who meet prior authorization criteria. This transitions to the ongoing BALANCE Model starting January 2027, with a Medicaid component potentially launching as early as May 2026. These changes represent the most significant expansion of Medicare anti-obesity medication coverage to date.

Cost comparison checklist